October 6, 2005

October 6, 2005, was the day preliminary forensic toxicology results gave investigators a striking new lead in the Memorial Medical Center deaths. The call from laboratory director Robert Middleberg brought Virginia Rider and prosecutor Butch Schafer evidence that appeared to align with their suspicions, while the condition of the bodies and the limits of postmortem testing left the meaning of that evidence unresolved.

The Preliminary Report

On September 22, state and federal investigators had sent tissue samples from eighteen Memorial bodies to National Medical Services, Inc., in Willow Grove, Pennsylvania. By October 6, the laboratory was still working on the cases. Middleberg called the attorney general’s office with an update, and Rider put him on speakerphone so Schafer and another special agent could hear. He cautioned that decomposition had made the samples less than ideal and that the analysis was not complete.

Middleberg reported that nine of the eighteen cases tested positive for morphine and that roughly five or six others tested positive for midazolam. The results immediately mattered because investigators were trying to determine whether LifeCare patients had detectable levels of morphine and other sedatives in their bodies. Schafer asked Middleberg to explain midazolam, underscoring that the call was an investigative briefing, not a settled interpretation of the findings.

The Match to Investigators’ List

The positive results coincided exactly with the names on the attorney general’s list of suspicious deaths, although the laboratory had not been told which names were on that list. That correspondence startled the investigators: the toxicology findings and their independently assembled list appeared to converge. Middleberg characterized the morphine concentrations as high, a description Rider and Schafer would remember.

The match strengthened the investigative case, but it did not answer every question the test results raised. The bodies had decomposed in heat for more than a week before recovery, making ordinary blood testing impossible and complicating the interpretation of drug concentrations in tissue. A volunteer pathologist had advised Rider that drugs might still be detectable in more durable tissues, including liver, brain, and muscle, or in fluid pooled in the abdomen. The October 6 findings came from that effort to recover evidence despite the delay and the condition of the remains.

What the Findings Could—and Could Not—Show

Later review emphasized that detecting a drug in postmortem tissue was not the same as establishing the dose given, the timing of administration, the cause of death, or a person’s intent. Experts considered whether the drugs might have accumulated through repeated doses, whether kidney or liver disease could have affected their clearance, and whether the combination could suppress breathing in patients not on respirators. They also compared the available clinical histories and records with the toxicology and the recorded timing of deaths.

The limits of interpretation became a source of disagreement. Coroner Frank Minyard consulted toxicologist Steven Karch, who argued that drug levels in bodies exposed to prolonged heat could not reliably establish the concentrations present before death and advised leaving medical causes undetermined. Forensic pathologist Michael Baden argued that the presence of the drugs remained significant even if the exact dose could not be reconstructed; Cyril Wecht disputed the claim that decomposition necessarily explained the high results, while acknowledging that his own test of the issue was a small, unpublished study. The October 6 report therefore became an important piece of evidence, not a final verdict.

A Turning Point, Not a Resolution

The investigation continued to assemble different kinds of evidence. Memorial pathologist John Skinner and laboratory director David Heikamp had recorded the names and locations of the dead while checking the hospital after evacuation; their notes and recollections could help establish when deaths occurred. Investigators also faced the risk that media coverage and discussions among witnesses might alter later recollections, making careful interviews and contemporaneous records especially important.

The later toxicology review expanded beyond the original eighteen samples: of forty-one bodies from Memorial and LifeCare analyzed by Middleberg’s laboratory, twenty-three tested positive for morphine, midazolam, or both. Those broader results required case-by-case consideration alongside medical records, because decomposition and patients’ differing conditions affected how the findings could be read. October 6 thus stands as a moment when a pattern emerged clearly enough to intensify the inquiry, while the questions of causation and responsibility remained open.